Agenus Inc
Company Profile
Business description
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body’s immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Contact
3 Forbes Road
LexingtonMA02421
USAT: +1 781 674-4400
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
316
Stocks News & Analysis
stocks
Chart of the Week: Soft earnings growth outlook for Australian banks
stocks
Coca-Cola earnings: Billion-dollar brands and consumer engagement remain growth priorities
stocks
Unwarranted drop in ASX share
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,299.50 | 115.00 | 1.25% |
| CAC 40 | 8,313.24 | 14.64 | -0.18% |
| DAX 40 | 24,856.15 | 131.70 | -0.53% |
| Dow JONES (US) | 50,121.40 | 66.74 | -0.13% |
| FTSE 100 | 10,479.60 | 125.76 | 1.21% |
| HKSE | 27,266.38 | 83.23 | 0.31% |
| NASDAQ | 23,066.47 | 36.01 | -0.16% |
| Nikkei 225 | 57,699.09 | 1,335.15 | 2.37% |
| NZX 50 Index | 13,499.68 | 53.31 | 0.40% |
| S&P 500 | 6,941.47 | 0.34 | -0.00% |
| S&P/ASX 200 | 9,045.30 | 129.30 | 1.45% |
| SSE Composite Index | 4,131.98 | 3.61 | 0.09% |